在重度抑郁症中治疗psilocybin真菌微剂量治疗:一个病例报告
Mariana Zarankin1, María S Pellegrini2, Francisco Zenteno3
1Psiquiatra, práctica privada, Ciudad Autónoma de Buenos Aires, Argentina. dramarianazarankin@gmail.com.
Vertex (Buenos Aires, Argentina)
|July 18, 2024
概括
西微剂量在治疗严重抑郁症方面表现有前途,为传统治疗提供了潜在的替代方案. 这项案例研究强调了年轻成人患者的完全缓解和改善幸福感.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 重度抑郁症 (MDD) 患病率很高,全球影响很大.
- 目前的MDD治疗有15-30%的不响应率和潜在的不良影响,如冷漠.
- псилоцибин治疗可以减少常规精神药物的剂量,并提供情绪/行为上的好处.
研究的目的:
- 介绍一项关于在被诊断患有MDD的患者中自给小剂量psilocybin的案例研究.
- 评估作为传统MDD疗法的辅助或替代品的psilocybin微剂量的疗效和安全性.
- 为了探索psilocybin微剂量对MDD患者情绪,行为和社会功能的影响.
主要方法:
- 一名患有MDD的19岁患者在 psilocybin 微剂量自我管理期间被监测了 7 个月.
- 干预涉及患者就自主性和降低西宾使用风险的咨询.
- 每周的评估包括临床病史,实验室测试和汉密尔顿抑郁症量表.
主要成果:
- 患者实现了MDD的完全症状缓解.
- 传统的药理治疗成功暂停,没有停止症状.
- 在沟通,社交互动和整体幸福感方面观察到显著的改善.
结论:
- 微剂量西洛似乎是一个有前途的治疗工具,用于管理严重抑郁症.
- 这个案例表明,在实现缓解和提高生活质量方面,有潜在的好处.
- 需要进一步进行严格的科学研究来验证这些发现,并确定psilocybin在抑郁症治疗中的作用.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
01:27Depressive Disorders: MDD and Dysthymia
90
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
90
01:30Electroconvulsive Therapy
30
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
30
01:22CNS Stimulants: Psychedelic Agents
137
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
137